Latest News | Emcutix Biopharmaceuticals Inks In-licensing Pact with WiQo

New Delhi, Apr 1 (PTI) Emcutix Biopharmaceuticals Ltd, a wholly owned arm of Emcure Pharmaceuticals, on Tuesday said it has signed an exclusive in-licensing agreement with Italian derma-cosmetic and medical device firm WiQo.

Under the pact, Emcutix will have the rights to import, promote, distribute and sell WiQo's non-invasive skin treatment product PRX-PLUS in India, the company said in a statement.

Also Read | Ladki Bahin Yojana April 2025 Installment Date: When Will Women Beneficiaries Receive 10th Kist of INR 1,500 in Maharashtra?.

PRX-PLUS has a feature with its deep-impacting formula that instantly tightens the skin, offering a non-invasive, pain-free alternative to traditional aesthetic treatments for those seeking effective results with convenience, it added.

Emcutix Biopharmaceuticals CEO Sathya Narayanan said PRX-PLUS is a unique and advanced skincare solution.

Also Read | Who Is Bajinder Singh? All About Self-Styled Punjab Pastor Fondly Called ‘Papa Ji’ by His Followers Sentenced to Life Imprisonment in 2018 Rape Case.

"With the strong marketing expertise of Emcutix, we are confident that PRX-PLUS will set new benchmarks in dermatological care, making cutting-edge skincare more accessible to consumers across India," he added.

WiQo CEO Cristian Dufeu said, "With PRX Plus, we are not only introducing an innovative, needle-free solution for skin tightening, but also empowering dermatologists and patients with a safer, more effective alternative in the ever-evolving world of aesthetic medicine. This collaboration is a testament to our commitment to bringing ground-breaking, science-backed innovations to new markets..."

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)